BioCentury
ARTICLE | Company News

ZymoGenetics, NVO interleukin deal

July 6, 2004 7:00 AM UTC

ZGEN granted Novo Nordisk (NVO) exclusive development rights outside North America to three proteins: interleukin 28A (IL-28A), interleukin 29 (IL-29) and interleukin 31 (IL-31). ZGEN said IL-28A and ...